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The saying, “gold is gold,” implies that gold, is synonymous with excellence, and as the most 
excellent of these descriptors, none are better. Since ancient times, gold has been sought out for its 
luster for coinage, leading to the ancient art of alchemy which focused solely in the isolation and 
manifestation of gold from other less valuable substances. Eventually whole nations would base 
their economy on the gold standard, and as science would progress, the chemico-physical 
properties of gold would be realized, leading toward more efficient electronics, devices, and 
implants. More recently, gold has been applied vicariously in the field nanomedicine, taking 
advantage of the unique characteristics that gold exhibits on the nanoscale.  
 
 One of the major setbacks of nanotherapy has been the immuno-detection and disintegration of 
nanosystems, designed in vitro, before reaching the site of action. A strategy of germinating 
nanosystems in situ might open new genera of solutions with more efficacious nanomedicine 
strategies. While synthetic surfactants have been used to produce metal nanoparticles using 
classical reduction chemistries, biomineralization has received particular consideration due to it 
being a “green” synthetic route, biocompatible, and the potential to allow designer particles 
retaining functionality. Within this paper we describe methods for which the environmental factors 
govern the structure and functionality of gold nanoparticles formed. Stemming from this we have 
moved toward an in cell synthesis, away from benchtop enabling pathology specifications for size, 
shape, and functionality of resulting nanoparticles. We anticipate future applications utilizing the 
technique developed here or methods similar to these, to propel the next major advancement in 
nanomedicine utilizing cellular machinery dependent on the pathology and not heavily on 
benchtop synthesis. The field of nanomedicine, being relatively new takes advantage of properties 
that materials will exhibit on a nanoscale, which are not as prominent or non-existent in their bulk 
counterparts, for applications in sensing of disease or therapeutic applications. For nano-gold, the 
technology to make these materials has existed since stained glass, but the ability to understand 
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1.1 NANOPARTICLES IN MEDICINE 
There has been a shift in medicine towards pre-emptive treatments through non-invasive 
localization of molecular disease biomarkers, and away from reactive therapies, which are 
often applied only after significant damage has been done.1–12 The aim of this shift is to 
recognize and treat the pathological chemistries, occurring in the sub-cellular level, before the 
disease spreads to organ or tissue levels where it can cause lasting damage. In order to 
recognize and treat these early stage diseases, combinatory theranostic (therapeutic and 
diagnostic) agents have emerged allowing for the treatment and characterization of pathologies 
with the ability to monitor the effectiveness of the therapy during treatment.13–38 This ability 
to monitor treatments throughout their application is especially important for treating diseases 
that are largely heterogeneous throughout the population (e.g. Cancer), as the effectiveness of 
one drug may not be equally effective across patients.39–47 These theranostic agents are 
principally based on imaging modality specific (MRI,47–105 X-ray,106–110 ultrasound,111–128 
ect…) nanoparticle contrast agents which are combined with therapeutics and targeting 
ligands.  
On the nanoscale, materials exhibit unique properties (i.e. magnetic, electronic, catalytic, and 
pharmacokinetic) from their bulk counterparts, which can be capitalized on for targeting, 
imaging, and treating disease.129–134 Compared to small molecule based therapeutic delivery, 
nanoparticles can deliver higher local concentrations of cytotoxic drug with minimal systemic 
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concentrations. This higher dosage to target with lower systemic dosage is a result multiple 
targeting ligands and drug molecules bound on the nanoparticles’ surface.  
Advancements in nanotechnology have allowed for potentially earlier identification and 
treatment of pathologies that are of cellular and molecular origin, as they are on similar size 
scales. Nanoparticles come in various forms of either soft particles (liposomes, dendrimers, 
and polymers), hard particles (quantum dots, gold, and magnetite), or a combination which can 
also occur naturally as proteins, micelles, viral envelopes and nanogels as examples.135–140 
Compared to small molecule based therapeutic delivery; nanoparticles can deliver higher local 
concentrations of cytotoxic drug with minimal systemic concentrations. As a therapeutic 
treatment, nanoparticles are capable of combining imaging modality-specific contrast and high 
drug payload in a medium with a high surface area to volume ratio capable of maximizing 
targeting ligands per particle; has been advanced toward these smaller scale disease pathways.  
The combinatory relationship between treatment and localization of disease models, largely 
taken advantage of exclusively within nanomedicine, is a relatively new approach to combating 
disease models in what is called theranostics (therapy and diagnostics).  Theranostic 
nanoparticles allow for a more appropriate application of personalized medicines as the 
imaging contrast provided allows the researcher or clinician to track the efficacy of the therapy 
real time or after the application. This personalization with concurrent monitoring of medical 
treatment becomes especially necessary when considering diseases that are largely 
heterogeneous such as cancer, whose current treatments are associated with emaciation and 
suffering, almost as highly as the disease. 
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Due to their capabilities of containing and delivering high localized-payloads of therapeutic 
drug and preemptively locating pathologies before they achieve tissue or systemic level effects, 
nanoparticles offer huge potential in molecular medicine.  
 
However, difficulties in their delivery to cellular targets exist as a barrier to their optimization 
and eventual clinical translation. These difficulties include, overcoming systemic filtration, 
immunological detection, and finally cellular internalization. For most nanoparticle 
applications more than 90% of the applied dosage will end up trapped in the liver, kidneys, 
spleen, and lungs (if >300 nm in size). This often undesirable accumulation is both a product 
of physical filtration combined with the actions of the immune system, recognizing the foreign 
nanoparticle agents and then removing them via urinary, biliary or fecal pathways. Even if the 
nanoparticles overcome these two huge barrier for cellular therapeutic delivery, they must still 
deliver their payload, and for the most effective delivery, this must be within the cell. For 
successful release the payload into the cytosol, crossing the plasma membrane by endocytic 
pathways followed by a mandatory endosomal escape must occur, but frequently if internalized 
by endosomes, their path will result in fusion with lysosomes or extracellular release. 
 
 In order to combat this, many researchers have taken advantage of cellular pathways 
already present within the physiology to either deliver or beneficially affect their therapeutics. 
Among these methods, many researchers have developed means for either reprogramming 
immune cells using nanoparticle technology, or label immune cells with nanotherapies, 
counting on the immune cells to deliver their enacting therapeutic.  More commonly, proteins 
specific to or more prolific within pathologic cells have been more commonly identified and 
4 
attached to nanotheranostics as targeting agents making them more specifically bind to the 
pathological tissue. 
 
1.2  ENVIRONMENTALLY SENSITIVE NANOPARTICLES 
The biomineralization process in nature largely utilizes protein-mediated mechanisms to form 
inorganic materials.141–144 Microorganisms have been forming and decomposing minerals in the 
earth's crust since soon after life on earth began. This has been taken advantage of largely through 
biomining, which involves microorganisms to extract metals from sulfide and/or iron-containing 
ores and mineral concentrates. Our ability to harness the natural capability of certain microbes to 
decompose a variety of mineral deposits is an old process that dates back to Roman times in the 
first century BC, and probably the Phoenicians before that. These early miners used microbial 
activity to leach copper from ore without being aware that microbes were involved. Although gold 
is inert to microbial action, microbes can be used to recover gold from certain types of minerals 
because as they oxidize the ore, they open its structure, thereby allowing gold-solubilizing 
chemicals such as cyanide to penetrate the mineral. In classical benchtop gold nanoparticle 
synthesis water soluble gold salts are mixed with surfactants and reactants containing functional 
groups such as thiols, amines, carboxylic acids, phosphates, and hydroxyls with either mild to 
strong reducing agent, heat, or sequestration to form reduced gold nanoparticles.  All of these 
reactants are present in physiological systems in forms of proteins, poly nucleic acids, metabolites, 
and membrane molecules. While the capacity to produce reductive environments may not be 
present within physiological systems, there is a temperature regulation process as well as 
sequestration through cellular membranes which could potentially be utilized to overcome energy 








2.1 SYNTHETIC GOLD NANOPARTICLES 
Gold has continued to be of scientific interest throughout the majority of mankind's existence. 
Initially for its luster, used as currency and in recent decades gold has been found to have many 
other applications in electronics and medicine. At the nanoscale, gold has been applied toward 
drug delivery, diagnostic imaging contrast enhancement, and photothermal ablative therapies. We 
describe a novel synthetic methodology to initiate morphological differentiation of highly 
controlled branched gold nanostructures. The dendritic, snowball, to polyvillic morphological 
differentiation was fundamentally driven by incubation temperature, time, and environmental pH. 
This approach can initiate a myriad of shapes using relatively low temperatures in aqueous solution 
wherein the branching can be finely tuned. The extent of the branching, size and morphology of 
the nanostructures was found to better facilitate cellular internalization with significant loading 
which could be detected by bright field imaging, hyperspectral confocal imaging, Raman 
spectroscopy and cellular transmission electron microscopy. Origin of near infrared absorbance in 
these nano-differentiations enunciate their probable use in broad spectrum of biomedical uses 
ranging from in vitro diagnostic to tissue penetrating detection agents. 
Gold nanomaterials have been extensively researched for biomedical applications due to their 
unique physical and chemical properties as well as their ease of manipulation, modification, and 
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biocompatibility145–148, 149,150,151. These nanomaterials possess unique optical properties due to 
surface plasmon oscillations of free electrons. These optical properties have been utilized for 
photothermal ablative therapies149,26, near infra-red (IR) imaging37,36, as well as gene and 
therapeutic delivery147,15. The absorbance maxima due to the surface plasmon resonance (SPR) 
effect is both dependent on the size and shape of the gold nanomaterials152,153. Spherical nano-gold 
has been shown to shift absorbance maxima toward the infra-red (IR) field of electro-magnetic 
radiations as size increases154–156. NIR is an interesting window for carrying out imaging due to 
the low tissue absorbance in the range. Hence, the application of gold nanomaterials offers a 
promising platform for achieving this goal.  The manipulation of the spectra is possible through 
size tuning; however, when the particles approach larger sizes, they no longer exhibit plasmonic 
effects and are no longer applicable as nanoparticle systems. Therefore, by manipulating the aspect 
ratio and circularity index of nano-gold, the effective size of the nanoparticle system is maintained 
while inducing a shift of the absorbance maxima toward the IR. Already, irregular morphologies 
of the Au nanoparticles (stars,37,157 cages,151,26 cones,158 rods,36 prisms159) has resulted in 
wavelength tuning of the  surface plasmon peak. These irregular shapes, in addition to the SPR 
absorbance shift, have larger surface area-to-volume ratios when compared to conventional 
spherical nanoparticles and can thus bind more drug molecules138,98,42,14,160, contrast agents73,74,60, 
or load greater amount of targeting ligands,161,162 as well as having a greater extent of cell 
interactions163–165. Branched and dendritic morphologies similar to those found in nature as 
snowflakes, neurons, villi and microvilli of the intestine are enticing as they maximize surface 
area. Fruitful results in developing hyperbranched dendritic nanostructures would result in a highly 
efficacious drug and contrast agent delivery vehicle. Thus far, the most successful attempts for 
high branching nanodendrons has been through lithography152, which is not practical for large 
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scale developments, and through seed mediated synthesis of gold nanostars (up to 7-8 branches)166–
168, which is limited by the seeding particles size. Branching in gold nanostructures results in a 
spectral shift towards the IR range as well as signal enhancement for Raman spectroscopy due to 
the SPR effect. These branches which act as nanoantennae, are responsible for this effect 
concentrating the optical energy into sub-diffraction volumes.37 As the absorbance maxima for 
nano-gold increases toward IR, the applicable penetrative depths for photothermal ablative 
therapies and near-IR imaging likewise increases. Here we report, a highly controllable single pot 
synthesis of hyperbranched gold ‘nano-polyvilli’ (NPV) where the branching can be controlled 
through incubation duration, temperature, and hydrogen ion concentration. We also generate 
nanoclusters of gold resembling nano-snowballs for the purpose of preliminary investigation 
towards biological applications using a more simplified, but still highly irregular morphology. 
These ‘nano-gold snowballs’ (NAuS) are generated at physiological temperatures (37 °C) and are 
effectively spherical, but with irregular edge characteristics providing unique SPR effects (>900 
nm absorbance peaks) as well as increasing the internalization in human transformed cells as 
followed by bright field imaging, Raman spectroscopy and cellular TEM. The logical extension of 
this synthesis at physiological temperatures would be the further investigation on the synthesis of 
gold nanoclusters in vitro in studies to follow.  
 
2.2 BIOMINERALIZED GOLD NANOPARTICLES 
Nanoparticles have been applied exhaustively for medical applications toward detection and 
therapeutic remediation of disease due to their high surface area to volume ratio enabling payload 
delivery of therapeutic drug molecules resulting in an increase in drug efficacy. In any nanoparticle 
synthesis system, the resulting size and shape are determined by the source material molecule and 
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concentration; surfactant molecule and concentration; and the catalytic reaction conditions such as 
oxidizing/reducing molecules, temperature, and pH. The size, shape, and functionality of the 
nanoparticles are especially important when considering specific biomedical application as the 
loading efficiency, pharmacokinetics, and biodistribution phisico-chemical properties per 
application will have different requirements for their optimized success.  
 
Gold nanoparticles have been extensively applied for biological applications due to their simplistic 
chemistry combined with their morphology dependent optical properties.169,170 For gold 
nanoparticle formation, the process involves at the minimum, chloroauric acid as a source material 
and a reducing agent (which can be the same surfactant molecule) (Scheme 1). Variations of the 
reducing agent molecule, as well as the reaction conditions (pH, temperature, incubation time), 
will result in different morphologies, sizes, and functionalities of resulting nanoparticles which in 
turn determine how they may be optimally applied.37,171 The ionic nanoparticle precursor 
(chloroauric acid) can be readily reduced by a variety of functional groups, however, formed gold 
nanoparticles are considered bioinert.172,173 This bio-inertness of gold nanoparticles, as well as the 
diverse range of applicable reductant molecules, has allowed researchers to develop biomimetic 
gold nanoparticles utilizing proteins or other biomolecules as scaffolds for reduction of ionic gold 
to plasmonic. Through this approach which utilizes biomolecules for reduction requires no 
additional steps for bioconjugation as the reducing biomolecules remain strongly attached 
following. If instead we were to germinate these gold nanosystems in vitro, utilizing 
phenotypically dependent cellular machinery, being independent of typical benchtop synthesis we 
could plasmonically sense said affecting phenotype providing a new versatile strategy for a cell-
level personalized medicine. 
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To illustrate, of the many functional groups which can participate in the reduction of gold 
nanoparticles, hydroxyls,174,175 thiols,169,176,177 and amines178,179 are most typically used in 
combination with surfactants for benchtop synthesis. These reactants are also ever present within 
the cellular environment as proteins, nucleic acid, lipids, and sugars. Their respective local 
concentration as well as the local pH and temperature, being reflective of the cellular health, pose 
as an intriguing potential for phenotypically dependent nanoparticle synthesis.  Here we 
demonstrate an approach that takes advantage of local cellular interactions to perform in vitro 
reduction of soluble ionic gold to plasmonic gold nanoparticles. Moreover, we prove that this in 
vitro reduction process occurs more prominently through specific proteins, of which, some are 
expressive of the current progression of the cellular disease. We demonstrate this potential for 
single cell differentiation of phenotype through breast cancer models can be harnessed for sensing 





RESULTS AND DISCUSSION 
 
3.1 SYNTHETIC APPROACH TO GOLD NANOPARTICLES 
 Branched and dendritic morphologies are enticing for their broad surface area similar to 
those found in nature as snowflakes, neurons, villi and microvilli of the intestine. Branching in 
gold nanostructures also results in a spectral shift towards the IR range as well as signal 
enhancement for Raman spectroscopy due to the SPR effect. These branches, which act as ‘nano-
antennae’, are responsible for signal enhancement of the optical energy into sub-diffraction 
volumes.180,181 As the absorbance maxima for nano-gold increases towards the IR range, the 
applicable penetrative depths for near-IR imaging and photothermal ablative therapies further 
improves. Therefore, a controlled synthesis of stable hyperbranched dendritic nanostructures 
would result in a highly efficacious drug and contrast agent delivery vehicle in addition to 
providing a superior sensing surface through plasmonics and surface enhanced Raman 
spectroscopy (SERS). Thus far, the most successful attempts for high branching nanodendrons has 
been through lithography,152 which seems to be not very practical for large scale developments.182–
184 Seed mediated synthesis of gold nanostars having up to eight branches166–168  have been 
reported, however the technique is limited by the use of seeding particles size and low number of 
branching arms. Other known approaches include synthesis through interfacial reactions,185 which 
are limited due to constrained directional growth  at the interfacial plane. A clear unmet synthetic 
need is a technique with supreme control over sprouting growth addressing all the issues 
mentioned above. This work develops a novel, non-seed mediated single pot synthesis method for 
11 
producing hyperbranched gold ‘nano-polyvilli’ with precise tuning of branch propagation via 
controlled duration of incubation, temperature, and hydrogen ion concentration (Scheme 1). 
 
3.1.1 3D anisotropic growth crystallization 
In diffusion limited non-equilibrium systems, spontaneous emergence of branched, dendritic, 
complex structures will evolve, as is seen in corrosion 186, bacterial growth 187,188, and the 
solidification of crystals 189–191. The simplest iteration of these non-equilibrium synthesis systems 
are interfacial reactions, wherein both reactants are not equivalently soluble in organic/aqueous 
solutions. While interfacial reactions are useful to develop nanowires and clusters of nanowires, 
they fail in creating truly three-dimensional dendritic growth. Our synthetic technique utilizes 
oleylamine as a reducing agent favoring low incubating temperatures and shorter incubation times, 
as longer and high temperature incubations are known to result in typical spherical 
morphologies.192,193 Carbon filtered de-ionized water was used as a solvent as opposed to hexane 
as conventionally utilized for nanowire synthesis.194 In a typical procedure, 5 mg HAuCl4 and 3 
µL (70%) oleylamine in 2 mL deionized water (pH 4) were incubated at 50 °C for 30 minutes.  
The formation of irregular gold nanoparticles of a highly polydisperse population was observed 
by transmission electron microscopy (TEM) (Figure 1A).  
This high polydispersity of particles is presumably due to the low solubility of reductant i.e. 
oleylamine in water, resulting in highly irregular interactions between the reactants. In order to 
increase the uniformity of interactions between oleylamine and Au3+ ions, polyethylene glycol 
(PEG) (mn=10,000 g/mol) was introduced as a surfactant, in order to promote the interactions 
between the water soluble gold ions and organically soluble surfactant. The concentration of PEG 
2
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was gradually increased until 250 mg/mL. At this concentration, predominant growth of three 
dimensional sprouting fingers were noticed which we termed nano-sprouts (Figure 1B-D). Several 
synthesis experiments were performed where the ionic salt, reductant, PEG, incubations, and 
hydronium concentration were varied (Scheme 1) in order to determine their specific roles within 
our synthesis method (Table S1) in order to gain a deeper understanding of the mechanisms behind 
the formation of 3D-crystalline nanocrystals. To quantify this branching shape indexes (SI) were 
calculated as from TEM images, as a quantitative measure comparing ratios of area to perimeter 
(calculated using ImageJ) to determine the uniformity of the particle edges. Values for SI range 
from 1-0, equation (1) with perfectly round, smooth-edged spheres with SI of one and infinitely 
thin lines with an SI of zero.  Since the edge conditions of these formed nanostructures are irregular 
in nature and non-symmetric, we describe the effective size of using the average Feret’s diameter 
(calculated using ImageJ) across all angles. Using the average Feret’s diameter and SI we are able 
to quantitatively compare outward branching growth, and uniform space filling growth between 
synthetic iterations through the positive/ negative correlations or lack thereof between these two 
values.  
When the synthesis was repeated without gold salt, small clusters of PEG/oleylamine were formed 
as evident from TEM (Figure 1E). When the synthesis was repeated without the use of reducing 
agent, formation of gold-PEG clusters was noticed indicating that both gold and oleylamine 
preferentially adsorbed to PEG (Figure 1F). When gold was replaced with sodium salt, during a 
typical synthesis, similar formation of clustering structures (Figure 1G) were observed. This 
indicates that formed clusters of PEG preferentially adsorbed both reactants (oleylamine and Au3+) 
followed by an initial nucleation and reduction. 
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3.1.2 Experimental growth characterization 
To further probe the role of the fatty amine within the reaction, we decided to examine the effect 
of head group, chain length, and concentration of oleylamine. When the nano-gold synthesis was 
repeated without a primary amine head group, i.e. 1-decene, clusters of gold salt and PEG identical 
to the synthesis using gold salt and PEG alone (Figure 2A) were noticed. This is a clear 
demonstration that the primary amine acted as a reductant within our system and in absence of 
such agent, reduction of gold salts was not feasible. Using a shorter carbon chain fatty amine i.e. 
dodecylamine at identical molar concentration, we observed an immediate cloudiness in the 
solution even before incubation, with no visible change in color after heating. From TEM images 
of the reaction with dodecylamine, we found gold particles with Feret’s diameters of 234 ± 36 nm 
with SI of 0.6 ± 0.1 after initial mixing. After heating at 50°C for 30 minutes we observed more 
branching (SI of 0.1 ± 0.0) with a smaller Feret’s diameter (153 ± 33 nm) (Figure 2B and C). 
Compared to the synthesis with oleylamine, these particles have smaller Feret’s diameter but with 
more space filling of the particle. From this, we can infer that the space filling of the gold structures 
is resultant of the lower molecular weight of the fatty amine dodecylamine allowing easier access 
for the molecule to penetrate. It turns out that the concentration of fatty acid reductant is also 
critical in governing the nucleation and propagation of sprouting growths. After analysing the 
variations of moles of oleylamine (0-0.0128 mmol), while keeping other constituents constant, we 
conclude that lower amounts of oleylamine resulted in decreased branching, while higher 
concentrations led to higher amounts of branch nucleation (Figure 2 D-F). 
To probe the role of the PEG as an intermediate surfactant within the reaction mixture we examined 
the polymer length in addition to the concentration (Figure 1A-D). Using equivalent w/w amounts 
of PEG (250 mg/mL), we found that shorter PEG chains led to smaller particles with fewer 
14 
branching (with similar morphology to particles formed with lower concentrations of oleylamine) 
and longer PEG chains resulted in more branching, but increased polydispersity (Figure 3A-D).  
To further probe this propagating-nucleation growth process, we monitored the morphological 
evolution over time through TEM. Discrete time points in this growth process were acquired 
through a quenching of the reaction by means of 100-fold dilution with deionized water. Observing 
nanostructure groupings of several short nano-sprouts with single origins, and their growth from 
5 to 30 minutes incubation at 50 °C through TEM (Figure 1D) imprinted an outward branching 
growth where the SI inversely correlated with the Feret diameter (ρ= -0.90) indicating that as the 
particles grew in size they became more irregular in their edge conditions. Beyond 60 minutes of 
50 °C incubation, highly ordered cubes, rods, spheres, and prisms formed in a polydisperse 
population (Figure S1). X-Ray photoelectron spectroscopy (Figure 4A-D) revealed the presence 
of ionic Au peak that these morphologies are not from a complete reaction/reduction of gold, and 
that the TEM images acquired at this time point are in effect ‘snapshots’(intermediates) of growth 
at that particular state. This is additionally corroborated through the observation of a continued 
visible color change of the solution if left unquenched post synthesis.  This color change, occurring 
at room temperature, is indicative of characteristic SPR shift due to size and/or shape change of 
plasmonic gold. We investigated the growth occurring at room temperature after 50 °C initiation 
(0 min to 24 hours) through a quenching of the reaction 100-fold with deionized water at the 
indicated time points. From this investigation, we discovered a high order of polyvillic branching 
(>50 branching arms), which occurs at room temperature after initial heating at 50 °C (Figure 5C) 
with the SI inversely correlated with the Feret diameter (ρ= -0.92). We repeated this with all 
combinations of 50 °C (5, 10, 20, and 30 minutes) and RT incubations (0, 0.5, 1, and 24 hours)   
(Figure 5). From these combinations we have found that with the combined incubations of 10 min 
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at 50 °C followed by 24 hour incubation at RT we were able to optimize for the highest ordered 
polyvillic branching nanostructures.  
As synthesized gold nanostructure growth occurs at temperature ranges between room temperature 
(~22°C) and 50 °C in aqueous solution, we aimed to explore growth at physiological temperatures, 
and by means of controlling the morphology.  This particular synthetic route piqued our interests 
as it could potentially lead to formation and controlled growth of gold nanostructures in vitro. 
Using the same reaction constituents for a polyvillic growth, we incubated the reaction vessel at 
37 °C in water bath for 30 minutes, and quenched the reaction by diluting the reaction mixture by 
1:100 fold using DI water. The synthetic products under the aforementioned conditions had well-
defined semi-spherical gold symmetry (Feret’s diameter of 268±39 nm) with irregular boundaries 
(SI of 0.6 ± 0.2), resembling nano-gold snowballs (NAuS). Using dynamic light scattering (DLS) 
we were able to confirm that the amount of water used in diluting the particles did not change their 
overall size, (Figure 6B) but did play a large role in the overall stability of the resulting particles. 
If quenched with 100 fold dilution, the NAuS were found to be stable for six days (Figure 6G), 
whereas if quenched with lower ratios of water to NAuS, the particle size would change over the 
course of a few days (Figure 6B-F). DLS, measures the speed at which the particles are diffusing 
due to Brownian motion. If the morphology of a particle alters in a way that affects this speed of 
diffusion, the hydrodynamic size will change. So, small changes in the aspect ratio of particle will 
directly affect the size; whereas changes in the diameter, which will hardly affect the diffusion 
speed, will be difficult to detect. We were able to use DLS for this analysis as the NAuS resemble 
‘typical’ spherical gold particles more than the polyvillic particles, resulting in more predictable   
interactions with light.195–197  
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Having successfully demonstrated gold nanoparticle synthesis in physiological conditions, we 
further investigated the potential influence of varying pH on morphology. A change in pH in 
cellular system could be indicative of cellular health and cell type.  To probe this potential 
influence of pH on morphology, we investigated resulting samples from propagation at varied pH 
environment and quenching. At low pH quenching (pH 4), we observed coral like gold reduction 
(Figure 6H) with lower Feret diameter (92± 36 nm) with a SI indicative of a more irregular 
boundary (SI of 0.1 ± 0.1) when compared to quenching at neutral pH. At high pH quenching (pH 
10), we observe villic protrusions of gold from a dense gold core (Figure 6I) with an average 
Feret’s diameter of 217± 64 nm and a SI of 0.1± 0.1. We interpret the morphological changes 
resulting from quenching pH as etching of the gold nanostructures at low pH, and branching 
occurring at high pH. These effects are further demonstrated through DLS (Figure 6J). 
 
 
3.1.3 Comparisons of shape toward in vitro applications 
Chemical composition,198 surface functionalization,199 shape and angle of curvature,163 
roughness,200 and hydrophobicity or hydrophilicity 201 decide the characteristics of cell surface and 
nanoparticle interactions. Irregularities in surface structures of nano-assemblies can be major 
contributors in cell-nanoparticle interactions and delegate cell internalizations. Given that the NPV 
are highly irregular in their boundaries, we presume that cellular  internalization would be more 
efficient than more spherical nanocrystals of similar size (NAuS) due to their geometry.131,202 To 
determine the effect of NPV surface irregularities contribution to cellular internalization, we 
incubated ~80% confluent MCF7 cells with NAuS, and NPV (for more detailed procedure see 
methods section). From ICP analysis of gold content of the spent medium collected from growing 
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cells treated with identical concentrations of either NAuS or NPV, we found greater amounts of 
gold remaining outside the cells treated with NAuS  compared with NPV (414% ratio, NAuS:NPV, 
of gold remaining in the spent medium).  This supports the concept that irregularities in the surface 
structure can enhance internalization.   
 Gold nanoparticles are favored as Raman spectroscopy probes due to their surface enhancement 
of Raman signal through plasmonics. To demonstrate the potential of our hyperbranched NPV as 
a superior Raman signal enhancer, we performed Raman spectroscopic cell microscopy on MCF-
7 cell line treated with NAuS or NPV. Raman intensities from C-H stretch modes in the cancer 
cells under controlled conditions are typically low with excitation laser set to 633 nm, while higher 
with excitation lasers set at lower wavelengths (Figure 7A). In order to ascertain chemical 
information from cellular Raman spectroscopy without high background signal from cell 
constituents, a Raman probe must be used. It will enhance Raman intensities of adsorbed 
molecules with an incident beam that would result in low intensities from non-adsorbed molecules. 
For plasmonic Raman enhancement cell spectroscopy, gold is idyllic as its absorbance maxima 
can be tuned (through shape manipulations) toward the IR and away from wavelengths which are 
heavily absorbed by physiological molecules. We can confirm that these enhanced Raman signals 
are in fact from gold nanostructures in that there are spectral signatures (1250 cm-1) only present 
from oleylamine and not present from the cells. Comparing both NPV and NAuS as Raman 
reporters it is clear that with a 633 nm incident beam, NPV has a predictably higher Raman 
enhancement, with the signal intensity resonating at a whole order of magnitude greater than with 
NAuS (Figure 7C and E). This higher Raman enhancement is likely due to the inherent shape of 
the NPV structure: NPV, being villic in nature has a higher surface area to volume ratio allowing 
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for more molecules to adsorb onto the surface as well as its additional magnetic field 
enhancements.  
Using hyperspectral enhanced confocal microscopy we were able to identify and discern both NPV 
and NAuS in solution using their near IR plasmonic maxima (Figure 8A, B and F, G).  While the 
NAuS are generally more spherical, through hyperspectral dark field imaging we are able to 
identify unique absorbance profiles which are unlike typical spherical particles due to their 
irregular edge. In solution, the NPV exhibited an absorbance maxima primarily at 700 nm, 
however, several absorbance profiles are present within this mixture.  Upon incubating particles 
with MCF-7 we observed a shift in plasmonic absorbance for both NAuS and NPV (Figure 8D, E 
and I, J). For NAuS, the absorbance spectra shifts from several non-uniform peaks with dual 
maxima between 500 and 700 nm, to a largely uniform peak centrally focused at approximately 
650 nm. The NPV Sample similarly showed a plasmonic shift and unification of absorbance 
maxima (Figure 8F, G and I, J). Although in contrast to the NAuS sample, the plasmonic 
absorbance profiles of the NPV shift toward shorter wavelength absorption upon interactions with 
cells. This blue shift, is not explainable through light interactions by the cellular membrane or 
through aggregation of the particles as these most typically result in red shift. This blue shift, 
unexplainable through typical cellular internalization of gold nanoparticle, could potentially be 
manifested through the degradation of the particles or through additional crystallization via 
biomineralization involving cellular biomolecules 203,204. We believe that this is caused by a 
continued crystallization of the gold nanoparticles in part because of the Raman enhancement of 
cellular biomolecules found in the NPV and NAuS samples but further investigation will be 
required to confirm this. 
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3.2 IN SITU GROWTH VIA CELLULAR MECHANISMS 
For gold nanoparticle formation, the process involves at the minimum, chloroauric acid as a source 
material and a reducing agent (which can be the same surfactant molecule). Variations of the 
reducing agent molecule, as well as the reaction conditions (pH, temperature, incubation time), 
will result in different morphologies, sizes, and functionalities of resulting nanoparticles which in 
turn determine how they may be optimally applied.37,171 The ionic nanoparticle precursor 
(chloroauric acid) can be readily reduced by a variety of functional groups, however, formed gold 
nanoparticles are considered bioinert.147,31,172,173 This bio-inertness of gold nanoparticles, as well 
as the diverse range of applicable reductant molecules, has allowed researchers to develop 
biomimetic gold nanoparticles utilizing proteins or other biomolecules as scaffolds for reduction 
of ionic gold to plasmonic. Through this approach, which utilizes biomolecules for reduction, 
requires no additional steps for bioconjugation as the reducing biomolecules remain strongly 
attached following. If instead we were to germinate these gold nanosystems in vitro, utilizing 
phenotypically dependent cellular machinery, being independent of typical benchtop synthesis we 
could plasmonically sense said affecting phenotype providing a new versatile strategy for a cell-
level personalized medicine. 
 
To illustrate, of the many functional groups which can participate in the reduction of gold 
nanoparticles, hydroxyls,174,175 thiols,169,176,177 and amines178,179 are most typically used in 
combination with surfactants for benchtop synthesis. These reactants are also ever present within 
the cellular environment as proteins, nucleic acid, lipids, and sugars. Their respective local 
concentration as well as the local pH and temperature, being reflective of the cellular health, pose 
as an intriguing potential for phenotypically dependent nanoparticle synthesis.  Here we 
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demonstrate an approach that takes advantage of local cellular interactions to perform in vitro 
reduction of soluble ionic gold to plasmonic gold nanoparticles. Moreover, we prove that this in 
vitro reduction process occurs more prominently through specific proteins, of which, some are 
expressive of the current progression of the cellular disease. We demonstrate this potential for 
single cell differentiation of phenotype through breast cancer models can be harnessed for sensing 
phenotypical variation with combined therapeutic potential on a cell-cell level.  
 
3.2.1 Au-Delivery Vehicle Design/ Characterization 
For gold nanoparticle formation, all of the the constituents (sans chloroauric acid) are present in 
cellular environments. however, if applied in bulk through diffusive manner, the caustic 
chloroauric acid will impart physiologically detrimental effects with bulk-not-nano interfacial 
reduction (if any reduction is to occur at all). Instances wherein nanoparticles of gold cannot occur 
in systems wherein the interface of reduction is occuring throughout the bulk and not on a 
nanoscale. However, if the ionic gold were deployed in discrete nanoscaled packets to the 
(potentially) reductive cell membrane, plasmonic nanoparticles could be formed. Using the cell 
membrane or other organelles/regions as a catalytic interface for gold nanoparticle reduction could 
result in variations of size, morphology, and functionalization existing through variations in 
phenotype of that respective region. For successful in vitro reduction of ionic gold by cellular 
interactions, it is necessary that the ionic gold: 
1) Is contained in discrete packets on nanoscale. 
2) Is not reduced by the vehicle in which it is contained. 
3) Will have the capacity to interact with the cells, and that biomolecules will have access to the 
gold ions for nanoparticle formation. While Chloroauric acid is readily reduced by a large variety 
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of functional groups, it is not readily reduced by hydroxyl groups, carbon-carbon single bonds, nor 
ether groups in acidic pH conditions.  Hydroxyl terminated Polyethylene glycol (mn=10,000 
g/mol) (PEG) composed of only these functional groups, was used to develop the ionic Au+ 
delivery vehicle. The reasoning for this choice being that polyol-based Au/Ag nanoparticle 
synthesis, where PEG could function as a reductant, typically require much higher temperatures 
(160°C)205 than utilized for cell culture (37 °C). 
 
In a typical process forming the ionic gold delivery vehicle, clusters of HAuCl4 (0.014 mmol) and 
PEG (0.050 mmol), mn=10,000 g/mol) are co-clustered in a sealed glass vial with 2 ml of carbon 
filtered deionized water (0.2 µm cellulosic membrane, pH=4). In acidic conditions, PEG molecules 
will cluster and positively charged gold ions will preferentially localize within the PEG clusters 
than within the acidic solution (Figure 9A, B). This mixture of ionic gold and PEG was then 
incubated in a 37°C water bath for 30 minutes to ensure thermal equilibrium is achieved before 
being diluted for analysis or cell treatment. To confirm that the gold in these Au-PEG clusters was 
ionic and not reduced, a UV-VIS electromagnetic spectra was recorded to determine plasmon 
formation or lack thereof (Figure 9C). This spectrum revealed a single absorbance maximum at 
213 nm, which is typical of ionic gold, with no observable peak in the 500-700 nm range that is 
characteristic of the surface plasmonic resonance of reduced gold. Additionally, no visible color 
change was observed if the solution was allowed to sit on the benchtop for 30 days (using only 
fresh Au-PEG clusters for all cellular applications). The discrete Au-PEG clusters were 288 ± 46 
nm in diameter, as quantified by transmission electron microscopy (TEM) (Figure 9B). From 
scanning electron microscopy-energy dispersive spectrum (SEM-EDS) (Figure 9D and E) we 
spectroscopically confirmed that the putative Au-PEG clusters do in fact contain gold and that the 
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gold is contained solely within the PEG clusters, not simply dispersed within the solution. Dark 
TEM contrast afforded by these clusters (Figure 9B), as well as through dark field hyperspectral 
imaging of the clusters in solution (Figure 9F and G), supports these observations.  The light scatter 
afforded through transmitted enhanced dark field hyperspectral imaging for the non-reduced ionic 
gold particles confirms the lack of surface plasmonic resonance peaks that would correspond with 
reduced gold. The light scattering peak at 420 nm is an artifact of the Vis-NIR liquid light guide 
which transmits light beginning at 420 nm.   
 
3.2.2 Intro to concept/capacity for in vitro reduction 
Au-PEG clusters were capable of enabling a  cellular reduction in human breast cancer cell  
monolayer population (MCF-7 and MDA-MB-231) when treated at an equivalent concentration to 
IC50 (in MCF-7) as determined by Thiazolium Blue (MTT) reduction assay (Figure 10A). In 
addition to Au-PEG treatments used; sodium-PEG (Na-PEG), Nifuroxazide-PEG (Nuf-PEG) 
(neither chemically conjugated), and chloroauric acid (Au3+) (without PEG) in equal molar 
concentration of the analyte were used for making comparisons toward their effect on cellular 
metabolism (Figure 10A and B). From this, we could conclude that at lower concentrations neither 
of the two treatments containing chloroauric acid are as detrimental to cell metabolism as the 
positive control treatment containing Nifuroxazide.  One interesting feature of these plots is a clear 
inflection point in the viability for Au-PEG treatments (not in the Au3+ treatments alone) in both 
cell lines, which appears to occur independently of the cell viability. This inflection does not 
represent an actual increase in cell viability, but could be indicative of internalized (non-reduced) 
gold ions after saturating the available reactive biomolecules. This positive linear relationship 
between Au3+ concentration and the absorbance of light used to quantify cell viability is supported 
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through our titrated relationship between Au3+ and A570 with concentrations of Thiazolium blue 
identical to MTT assay concentrations (Figure 10C). We were able to first confirm the transition 
of ionic to plasmonic gold through the spectral library obtained from enhanced dark field 
hyperspectral imaging of Au-PEG clusters reduced through interactions with living MCF-7 cells 
(Figure 11A and B). To confirm that these plasmonic nanoparticles were internalized and not 
simply on the cell surface, cellular TEM imaging of Au-PEG clusters after incubation with 
growing cells (osmium tetroxide and uranyl acetate staining) was performed (Figure 11Ci). In the 
course of this reduction, there was an observable electron density focusing in formed particles as 
well as with a dark continuous irregularly shaped border along the periphery (Figure 11Ci). To 
confirm that gold nanoparticle formation is occurring en route to cellular internalization and not 
by undesired reactions to either the culture plate coating or the culture media, we undertook control 
experiments. With a high number of primary amines on the adherent culture plate surface (poly-
L-lysine (PLL) coating), a reduction of ionic gold within the solution of the culture plate could 
potentially occur. After incubating the ionic Au-PEG clusters for 24 hours at 37°C no reductive or 
structural changes were observed (Figure 11D), rejecting out hypothesis that amine functionalities 
present in adherent culture plate surface (i.e. poly-L-lysine) involved in gold reduction. Bovine 
serum albumin (BSA), a protein nutrient source within our culture media, is capable of gold 
nanoparticle reduction with the aid of mild to strong reductants or through pH manipulation.204,206 
We determined BSA not as the source of gold biomineralization in our system, as the full culture 
media (containing BSA) was not able to reduce the ionic gold clusters (24h, 37 °C), confirmed 
through TEM images of this treatment solution (Figure 11E). For BSA based biomineralization 
procedures, it is necessary to include strong/mild reductants or pH manipulation, contrary to these, 
neither are present within our system.204,206 
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3.2.3 Biomolecule Investigation 
Having demonstrated in vitro formation of plasmonic nanoparticles via action of cellular 
biomolecules, while intriguing, poses no value unless information pertaining to the interacting 
biomolecules can be determined and it can be demonstrated in other pathologies/cell lines. To 
determine which biomolecules were participating in this in vitro reduction pathway and if this were 
applicable across other model cell lines, ionic Au-PEG treatments were applied to MCF-7 as well 
as to MDA-MB-231 and the resulting Raman spectral maps compared against sodium PEG (Na-
PEG) and chloroauric acid controls. The resulting spectra of MDA-MB-231 treated with Au-PEG 
were markedly enhanced by magnitudes compared to cells treated with Na-PEG or just chloroauric 
acid, indicating plasmonic enhancement (Figure 12A-C). This enhancement can only arise from 
species within a range less than 100 nm. This, plasmonic enhancement only found with the Au-
PEG treatment additionally confirmed the necessary role of discretion of the Au+ cations within a 
delivery vehicle for plasmonic nanoparticle formation. These resulting Raman spectral maps also 
provided chemical information pertaining toward the affecting biomolecules participating in this 
in vitro nanoparticle formation. These Raman spectra contain characteristic peaks arising from 
lipid (1175-1385, 1446-1477, and 2849-2969 cm-1), and proteins (1590-1650 cm-1).207 
Additionally to this, lack of enhanced characteristic phosphate peaks at 2380-2450 cm-1 in the 
enhanced spectra allowed us to confirm that phosphates from the sodium phosphate buffer and/or 
the nucleic acids are not participating in this gold reduction.207 However, simply the presence of 
amide, CH3 and CH2 peaks provide hardly enough information to be considered viable as a 
diagnostic tool nor does this information prove to be enough to understand what is happening 
within our system.  
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To more precisely determine the biomolecules engaged in this in vitro reduction pathway and 
which portions of the cell they originate, cellular fractions were separated by density (through 
differential centrifugation) and the presence of plasmonic gold investigated through surface 
enhancement of Raman spectra (SERS) (Figure 12D and E). Mechanical lysis by tip sonication 
(30 s @ 1 Amp) of MCF-7 cells treated with the ionic Au-PEG, or untreated cells was used before 
separating by density into  
1. Nuclei and large organelles (Red) 
2. Mitochondria, lysosomes, peroxisomes, medium organelles (Yellow) 
3. Cellular membrane fragments (Purple) 
4. Highly soluble peptides/ cytosolic molecules (Blue) 
For an in depth procedure for differential centrifugation see materials & methods section. For these 
cellular fractions respective Raman spectra collected for both cells treated and untreated with Au-
PEG. An enhancement of the Raman spectra was observable for fractions one (nuclei) and three 
(Membrane molecules). Both of these fractions contained prominent amide peaks at 1590-1650 
cm-1207. The presence of SERS in fractions one and three indicated that at least two types of gold 
nanoparticles are being reduced within this in vitro reduction system and that with a given spectra 
of treated cells the separation of information from these respective peaks can be obtained (Figure 
12D). 
From this prominent amide peak especially present in the nuclear fraction, we are led to believe 
that proteins could potentially be playing a significant role in this in vitro reduction pathway being 
supportive of our initial reasoning. To confirm that proteins are involved in this in vitro gold 
nanoparticle formation and to additionally determine which proteins these are; a simple sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate proteins 
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found within the nuclear fractions from cells treated with either ionic Au-PEG, Na-PEG, or 
untreated. Our hypothesis for this simple analysis being that protein expression between treatments 
may be affected and that those nanoparticle-bound proteins which enable in vitro reduction, would 
not pass through the gel (resulting in missing protein bands) due to the small size of the gel pores 
(2-5 nm), compared to the large size of the gold nanoparticles (>20 nm). The intensity of expressed 
protein bands would be compared between these treatments (Au-PEG, Na-PEG, and no treatment) 
via Coomassie Blue staining (excluding proteins outside of the protein ladder size range 10-250 
kDA).  
 Initially, we did not find any difference of expressed proteins between the treatments for all 
treatments (Figure 13A and B). This information posed two possible major implications -- being 
that none of our treatments were affecting protein expression and that all proteins which were 
running through the gel in detectable quantities were not adhered to the gold nanoparticles. 
Another possible explanation however, could be that one of the solutions used for preparing the 
protein for SDS-PAGE separation was able to interfere with the protein-gold interactions, 
effectively freeing the proteins from the nanoparticles. The primary candidate considered for this 
interference possibly ‘freeing’ the proteins being β-mercaptoethanol (βME), as it is known to 
function as a capping/ quenching agent for gold nanoparticle syntheses as well as being capable of 
breaking Au-SH bonds between nanoparticles and protein.8 To determine whether βME actually 
was responsible for this ‘freeing’ of Au-bound proteins we were prompted to run an additional gel 
comparing protein migration from the nuclear fraction of cells either treated with Au-PEG, Na-
PEG, or no treatment  in duplicate, but half without βME (Figure 13A). From observing the these 
protein migrations comparing cellular treatments with and without βME, we found that four 
protein bands had lower intensities (almost complete lack of presence) within the Au-PEG-No 
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βME treatment (Figure 13A and B) while all other bands for all other treatments were identical 
(Figure 13A). These identical protein band intensities indicate that neither our Na-PEG nor the 
Au-PEG treatment affected the protein expression of proteins found within the nucleosome, while 
proteins of four different sizes (Within 10-250 kDA) within that layer are attached to the formed 
plasmonic gold nanoparticles after their formation.   
Having observed protein impedance within the nuclear fraction of the ionic Au-PEG treated cells, 
we aimed to identify these proteins through LC-MS protein fingerprinting. To do this, we would 
remove proteins not contributing to in vitro formation of plasmonic gold by running the nuclear 
fraction of ionic Au-PEG treated cells for an excess of time without βME then separate the top 
portion of the gel containing the wells from the bulk (Scheme 2). The proteins/ gold particles were 
then extracted from gel portions using a diffusion mediated passive elution method.208–210 These 
extracted proteins were then briefly trypsinized to fragment the proteins present from extractions 
and centrifuged @ 6,000 x g to pellet any gold nanoparticles out of solution and then the 
supernatant containing soluble protein fragments was analyzed via LC-MS with MASCOT 
analysis (Matrixscience, Boston, MA) to identify which proteins were represented by the protein 
fragments. Within the top portion of the gel which contained proteins which were impeded through 
the gel most, there were 864 different protein fragments, of which 497 were uniquely found within 
the top portion of the gel (not present within the bulk of the gel). Of these fragments we excluded 
those with a protein score lower than 22 (α<0.05), and which the representative proteins were 
larger than the upper bound of the standard protein ladder (250 kDA). The remaining protein 
fragments which denote proteins which were unable to migrate through the gel due to their 
interactions with formed plasmonic gold nanoparticles represented 83 different proteins (Table 1 
see supplemental for full protein fragment data). Of these proteins, various forms of Keratin were 
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ubiquitous with protein scores two orders of magnitude greater than the minimum threshold of 21, 
implying high significance. The notion that Keratin mediated in vitro formation of plasmonic gold 
nanoparticles within our system is highly likely, as Keratin has previously been demonstrated 
capable of forming plasmonic gold nanoparticles via benchtop synthesis.211 However, in this 
benchtop synthesis method reductive additives are necessary for nanoparticle formation, it is 
possible that the living cells are providing reductive capabilities through NADH, ATP, or other 
means. This capacity for Keratin to reduce plasmonic gold nanoparticles from ionic is principal 
from its highly regular disulfide bonding, which is also causal of Keratin durability and highly 
ordered secondary structure. From quantification of the amino acid distribution resulting from the 
protein fragmentation analysis of from our in vitro reduction system, there is a lower occurrence 
of thiolated amino acids than are usually found in the Keratin proteins found (Figure 13) 
(http://www.uniprot.org/).  Additionally, there are also lower distributions of amino acids with 
heterocyclic secondary or tertiary amine and hydroxyl functional groups with an increase in 
representative primary amines within the fragment sequences (Figure 13 C). If these functional 
groups were ones that preferentially interact with gold (Thiols,8,169,176,177 proline,212 and 
histidine,213) this phenomenon could be explained as protein fragments which contain those 
functional groups or more of them would remain bound to the plasmonic nanoparticles which 
remained in the pellet not to be analyzed via LC-MS.  If any of these proteins which are largely 
representative for a particular stage of disease (i.e. Keratin levels for breast cancer), this method 
for enabling cells to form plasmonic gold nanoparticles has the potential for determining the stage 








From our initial analysis, wherein we characterized the clustering organization of ionic gold, 
oleylamine, and PEG, we can be certain that the initiation of gold reduction occurs within these 
clusters. While this reduction/nucleation is occurring within these clusters, The PEG will adsorb 
to the surface of the molecular gold, rearranging within the cluster to minimize the surface potential 
of the reduced gold. As this rearrangement of PEG occurs, oleylamine and Au3+ ions will 
concurrently follow, as they are located within the PEG clusters preferentially to the aqueous 
environment. As this predicted nucleation and rearrangement occurs, anisotropic growth continues 
dependent on both the diffusivity of the reaction constituents and the adsorptive properties of PEG 
toward molecular gold. This anisotropic growth process brings about a propagation of the 
nucleation site. As we have demonstrated, the morphological evolution of this synthesis is affected 
by temperature, PEG chain length as well as both hydrogen ion and reaction constituent 
concentrations. The effective solubility and in turn diffusivity of the reaction constituents are all 
affected by the temperature as well as both hydrogen ion and reaction constituent concentrations. 
The solubility of the reaction constituents as well as the total energy of the system should both 
affect the way in which PEG adsorbs onto molecular gold and the corresponding gold diffusion 
characteristics, thus changing and manipulating the resulting morphology. We demonstrate high 
levels of morphological control through pH, temperature and concentration control to develop a 
myriad of asymmetrical gold nanostructures. Of these structures, we have even produced 
hyperbranched gold nano-polyvilli which have more branching than any other morphologies of 
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nano-gold developed thus far relative to overall particle size. These hyperbranched gold nano-
polyvilli hold great potential for drug and contrast agent delivery in addition to providing a superior 
surface for plasmonic sensing and surface enhanced Raman spectroscopy. We have demonstrated 
these benefits against a more spherical control. Upon this investigation however, the apparent 
interactions are not entirely clear leading to question whether their growth continues upon 
interactions with the cells and if these cellular interactions can mediate this growth. We have 
illuminated a synthesis system in which ionic gold and PEG clusters are reduced in vitro through 
biomolecular interactions. We envision future applications propelling the next major advancement 
in nanomedicine wherein the treatment focuses on fluid-form small molecules in which 
nanostructures occur en route, utilizing cellular machinery46,214,215 and dependent on the local 
histopathology of the tissue providing highly specific synthesis opportunities for sensing, therapy 
or control over local physiology. 
 
 
4.2 FUTURE AIMS 
To further this technology, strives must be made to protect the ionic gold while in transit to the 
targeted cells. Doing so will prevent premature gold nanoparticle formation, through interactions 
with extracellular proteins or off target cells. We plan to accomplish this through liposomal 
delivery mechanisms, or through inverted solid lipid particles coated with surfactant.  When 
designing these carrier vehicles for ionic gold delivery we must take special care to select 
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APPENDIX A: METHODS 
 
Unless stated otherwise, all material and reagents were purchased from Sigma–Aldrich 
and were used without further purification. 
Gold nanostructure synthesis 
In a 20 mL scintillation vial, 5 mg of HAuCl4 and 500 mg of PEG (mn=10,000 g/mol) are 
mixed in sealed glass vial with 2 µL oleylamine (70% g/mL; w/v) and 2 mL of carbon filtered 
deionized water (0.2 µm cellulosic membrane, pH = 4). This mixture was incubated in either a 37 
or 50°C water bath for up to 30 minutes before being diluted 100 fold with carbon filtered 
deionized water  (0.2 µm cellulosic membrane, pH = 7) immediately or after a room temperature 
incubation (up to 24 hours). 
  
Dynamic light scattering  
Hydrodynamic diameters were determined using a Malvern Zetasizer ZS90 particle size 
analyzer, while scattered light was collected at a fixed angle of 90°. A photomultiplier aperture of 
400 mm was used, with the incident laser power adjusted to obtain a photon counting rate between 
200 and 300 kcps. Measurements for which the measured and calculated baselines of the intensity 
autocorrelation function agreed to within +0.1% were used to calculate hydrodynamic diameter 
values. Hydrodynamic diameter was analyzed using number distribution in accordance with 
various previous reports. All determinations were made in multiples of 3 consecutive 
measurements with 15 runs each. 
 
Enhanced darkfield hyperspectral imaging  
Optical and hyperspectral images were captured at 60X magnification under enhanced darkfield 
illumination using the CytoViva hyperspectral imaging system (Auburn, AL). This hyperspectral 
imaging system couples an enhanced darkfield illuminator with optical and hyperspectral CCD 
cameras. The hyperspectral images, also called datacubes, were collected using the “pushbroom” 
method. The spectral data (400 – 1000 nm) was acquired one pixel row at a time. The acquisition 
was facilitated by a motorized stage. The hyperspectral analysis software ENVI compiled this 
spectral and spatial data into a datacube, in which each pixel contained spectral data. Spectral 
libraries corresponding to the NPV and NAuS were built from the images of exposed cells. 
These libraries were filtered against a negative control image (cells only, Supplemental Figure 1) 
to ensure no false-positive mapping of the nanoparticles. Using the Spectral Angle Mapper 
(SAM) algorithm, the spectral libraries were compared to their respective images. 
 
Au-PEG Cluster Synthesis 
 In a 20 ml scintillation vial, 5 mg of HAuCl4 and 500 mg of PEG (mn=10,000 g/mol) are 
mixed in sealed glass vial with 2 ml of carbon filtered deionized water (0.2 µm cellulosic 
membrane, pH = 4). This mixture was incubated in a 37°C water bath for 30 minutes before being 





The absorption spectra for NAuS and Au-PEG clusters were acquired in a Genesys 10S UV−vis 
Spectrophotometer (Thermo Scientific, Rockford, IL) as prepared with no further dilution. 
 
DLS 
Hydrodynamic diameters were determined using a Malvern Zetasizer ZS90 particle size 
analyzer, while scattered light was collected at a fixed angle of 90°. A photomultiplier aperture 
of 400 mm was used, with the incident laser power adjusted to obtain a photon counting rate 
between 200 and 300 kcps. Measurements for which the measured and calculated baselines of 
the intensity autocorrelation function agreed to within +0.1% were used to calculate 
hydrodynamic diameter values. Hydrodynamic diameter was analyzed using number distribution 
in accordance with various previous reports. All determinations were made in multiples of 3 
consecutive measurements with 15 runs each. 
 
Transmission electron microscopy measurements (TEM) 
For TEM, 2.5 μL of the as-prepared gold nanoparticles were placed on a 300-mesh carbon film 
supported by a copper grid and allowed to stabilize for 2 min. A filter paper was then used to 
remove liquid for thin liquid films formation and then allowed to air dry while covered. Images 
were obtained using a Jeol 2010 cryo-electron microscope operating at 200 kV, and using different 
degrees of defocus to obtain an adequate bright contrast. Images were recorded on a Gatan 
UltraScan 2kx2k CCD. These CCD images were processed and analyzed with ImageJ 
(http://rsbweb.nih.gov/ij/) version 1.48. To determine the shape index and Feret’s diameter for 
individual particles the line tool was used to set the scale of pixels/nm ratio, then images were 
converted to 8-bit. After 8-bit conversion, the threshold tool was used (auto/default) to set min and 
max pixel values to 0 and 255 for particle analysis. 
Scanning electron microscopy (SEM) and electron dispersion spectroscopy (EDS) 
For SEM-EDS, several 3 μL drops of the as-prepared Au-PEG clusters were placed on a strip of 
copper tape placed on an SEM sample grid and allowed to stabilize for 5 min. A filter paper was 
used to remove liquid for thin liquid films formation and then allowed to air dry while covered. 
Images were obtained using a Hitachi S4700 scanning electron microscope with Oxford 
Instruments ISIS EDS X-ray Microanalysis System. SEM images were captured using a 10 kV 
accelerating voltage, a 10 μA emission current, and a 12 mm working distance, adjusting sample 
height for coarse focus and low degrees of defocus to obtain an adequate secondary electron 
images and EDS. Images were recorded using a Centaurus BSE detector. 
 
Human transform cell culture 
MCF-7 cells (ER (+) human breast cancer cells) were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM; Sigma) supplemented with 10% fetal bovine serum (FBS) and 1x Penstrep in 
T25 culture flasks (Cellstar; Germany) and were incubated at 37 °C in a 99% humidified 
atmosphere containing 5% CO2. Cells were regularly passaged by trypsinization with 0.1% trypsin 
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(EDTA 0.02%, dextrose 0.05%, and trypsin 0.1%) in DPBS (pH 7.4). Non-synchronized cells were 
used for all the experiments. 
Control treatments with Au-PEG clusters 
Both 150 µl of as-prepared Au-PEG clusters and 250 µl of fresh media (repeated with spent media) 
were admixed in a 2 ml microcentrifuge tube and incubated in a water bath for 24 hours. From 
these samples 2.5 µl would be extracted for TEM analysis as described in the TEM measurements 
section. 
To an empty poly-L-lysine treated culture plate 2 ml of as-prepared Au-PEG clusters was added. 
This container was incubated at 37 °C in a 99% humidified atmosphere containing 5% CO2 for 24 




Cell culture treatment with Au-PEG clusters for Raman spectroscopic analysis 
Samples of Au-PEG were diluted in DMEM medium (0.1% FBS) at a ratio of 3:5 (Au-
PEG:DMEM) and this mixture. After removing old media, this mixture would incubate on a 
monolayer of MCF7 cells (grown on glass slides until ~80% confluency) growing at 37 oC with 
5% CO2 for 4 hrs. After this incubation period growth medium was discarded and cell monolayer 
was washed with DPBS before fixing with 37% Formaldehyde solution. Raman spectra were 
acquired on cells incubated with Au-PEG treatment and on control cells lacking treatment in 
reflection mode (LabRAM HR 3D Horiba confocal microscope). Laser light was focused through 
a 100x, NA 0.8 objective into the sample plane and the scattering was collected in the reflection 
geometry using the spectrograph coupled with an Andor Newton back-illuminated EMCCD 
camera. The excitation wavelength for the measurements was set to 633nm and the power was set 
to 8 mW at the sample with a 0.2s acquisition time. Raman shift from 1000 to 3050 cm–1 was 
collected at 8 cm–1 spectral resolution. Intensities of select vibrational modes were selected to 
generate the Raman images.  
 
Cell culture treatment with Au-PEG clusters for transmission electron microscopy 
Samples of Au-PEG were diluted in DMEM medium (0.1% FBS) at a ratio of 3:5 (Au-
PEG:DMEM) and this mixture. After removing old media, this mixture would incubate on a 
monolayer of MCF7 cells (grown in T-25 flask until ~80% confluency) growing at 37 oC with 5% 
CO2 for 4 hrs. After this incubation period growth medium was discarded and cell monolayer was 
washed with DPBS before trypsinizing the treated cells. Cells were harvested in small 1.5 mL 
centrifuge tubes and collected in DPBS before fixing using Karnovsky's Fixative. After the cell 
pellet was fixed in a Karnovsky's Fixative in phosphate buffered 2% Glutaraldeyde and 2.5 % 
Paraformaldehyde. Microwave fixation was used with this primary fixative and the tissue is then 
washed in Sorenson’s phosphate buffer with no further additives. Microwave fixation was also 
used with the secondary 2% Osmium Tetroxide fixative, followed by the addition of 3% Potassium 
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Ferricyanide for 30 minutes. After washing with water, saturated Uranyl Acetate was added for 
enbloc staining. The tissue was dehydrated in a series of increasing concentrations of ethanol. 
Acetonitrile was used as the transition fluid between Ethanol and the Epoxy. Infiltration series was 
done with an epoxy mixture using the epon substitute Lx112. The resulting blocks were 
polymerized at 90C overnight, trimmed and ultrathin sectioned with diamond knives. Sections 
were stained with Uranyl Acetate and Lead Citrate, and examined or photographed with a Hitachi 







































































Figure 9 Characterization of ionic Au-PEG delivery vehicle. Representative TEM images of PEG (A) 
and ionic Au-PEG clusters (B).   UV-Vis absorbance spectrum of ionic Au-PEG clusters (200-800 nm) 
(C). Electron dispersion spectrum (D) of ionic-Ai-PEG clusters captured from SEM-EDS of (E). Purple 
spectra corresponding to clusters signal and Blue spectra corresponding to background.   Spectral 
intensity of light scatter (F) obtained through hyperspectral enhanced dark field imaging of discreet Au-




Figure 10 Cell viability of MCF-7 (A) and MDA-MB-231 (B) cells as assessed via thiazolium blue 
(MTT) metabolic assay for cells treated with Na-PEG (Blue), Au3+ (Green), Au-PEG (Red), and 
Nifuroxazide mixed with PEG (Black). Titrated light interactions between ionic-PEG mixtures (same 







Figure 11 Confirmation of in vitro reduction occurring en route. Spectral intensity of light scatter (A) 
obtained through hyperspectral enhanced dark field imaging of MCF-7 Cells treated with Au-PEG 
clusters (B). Schema (C) with representative TEM images describing reduction of ionic Au-PEG clusters 
(Ci), upon their interaction with cells (Cii). TEM images from extracted solution of ionic Au-PEG 
treatments to cell culture plates with magnification of unchanged Au-PEG cluster (D), and fresh cell 
culture media incubated with Au-PEG clusters (E). 
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Figure 12 Analyses of biomolecules implicit in the in vitro nanoparticle formation, their locations 
within the cells and applications in other cell lines. Raman spectra (A) of MDA-MB-231 cells 
treated with either Na-PEG (Blue), Au+ (Green), or Au-PEG clusters (Purple), with inset bright 
field image (B), and Raman spectral map of 2800-3000 peak intensity (C). Raman spectra of 
cellular fractions obtained from MCF-7 cells treated with Au-PEG (D) or without treatment (E). 
Each of these spectra within D and E, are sourced from cellular fractions of the nucleus and large 
organelles (Red); mitochondria, lysosomes, and other medium sized organelles (Yellow); 




Scheme 2 Describing the process for separating Au-bound proteins from non-bound through gel 




Figure 13 Semi-quantitative analysis of proteins participating in the in vitro nanoparticle formation. SDS-
PAGE stained with Coomassie Blue with intensity plots overlaid of protein from the nuclear fraction of 
MCF-7 cells (A) untreated (Green), treated with Na-PEG (Blue), or Au-PEG (Yellow) with standard SDS-
PAGE conditions (lighter shaded colors, top three lanes), or without β-mercaptoethanol (darker shaded 
colors, bottom three lanes). Protein band intensities of MCF-7 cells treated with Au-PEG clusters 
between standard SDS-PAGE conditions and without β-mercaptoethanol (B). Amino acid distributions of 
protein fragments (C) released from formed gold nanoparticles located within the nuclear fraction of 
MCF-7 cells treated with Au-PEG through trypsinization as determined via LC-MS (Solid bars) as 
compared to the amino acid distributions of proteins which those fragments represent in their native state 




Table 1 Proteins which are completely unique to the top portion of the electrophoresis gel (Scheme S1) 
as determined by LC-MS with respective protein scores/masses (with Protein scores >21) 
